Table of Contents Author Guidelines Submit a Manuscript
Journal of Nanomaterials
Volume 2011, Article ID 163791, 16 pages
http://dx.doi.org/10.1155/2011/163791
Review Article

Evaluating the Controlled Release Properties of Inhaled Nanoparticles Using Isolated, Perfused, and Ventilated Lung Models

Medical Clinic II, Department of Internal Medicine, Justus-Liebig-Universität Giessen, Klinikstraβe 36, 35392 Giessen, Germany

Received 31 August 2010; Accepted 22 November 2010

Academic Editor: Hugh D. Smyth

Copyright © 2011 Moritz Beck-Broichsitter et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Taylor and I. Kellaway, “Pulmonary drug delivery,” in Drug Delivery and Targeting, A. Hillery, A. W. Lloyd, and J. Swabrick, Eds., pp. 269–300, Routledge Chapman & Hall, London, UK, 2001. View at Google Scholar
  2. H. Bisgaard, C. O'Callaghan, and G. C. Smaldone, Eds., Drug Delivery to the Lung, Informa Healthcare, New York, NY, USA, 2002.
  3. H. M. Courrier, N. Butz, and TH. F. Vandamme, “Pulmonary drug delivery systems: recent developments and prospects,” Critical Reviews in Therapeutic Drug Carrier Systems, vol. 19, no. 4-5, pp. 425–498, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. D. A. Groneberg, C. Witt, U. Wagner, K. F. Chung, and A. Fischer, “Fundamentals of pulmonary drug delivery,” Respiratory Medicine, vol. 97, no. 4, pp. 382–387, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Gessler, W. Seeger, and T. Schmehl, “Inhaled prostanoids in the therapy of pulmonary hypertension,” Journal of Aerosol Medicine, vol. 21, no. 1, pp. 1–12, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Mobley and G. Hochhaus, “Methods used to assess pulmonary deposition and absorption of drugs,” Drug Discovery Today, vol. 6, no. 7, pp. 367–375, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. N. R. Labiris and M. B. Dolovich, “Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications,” British Journal of Clinical Pharmacology, vol. 56, no. 6, pp. 588–599, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. N. R. Labiris and M. B. Dolovich, “Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications,” British Journal of Clinical Pharmacology, vol. 56, no. 6, pp. 600–612, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. X. M. Zeng, G. P. Martin, and C. Marriott, “The controlled delivery of drugs to the lung,” International Journal of Pharmaceutics, vol. 124, no. 2, pp. 149–164, 1995. View at Publisher · View at Google Scholar · View at Scopus
  10. J. G. Hardy and T. S. Chadwick, “Sustained release drug delivery to the lungs. An option for the future,” Clinical Pharmacokinetics, vol. 39, no. 1, pp. 1–4, 2000. View at Google Scholar · View at Scopus
  11. Y. Xie, P. Zeng, and T. S. Wiedmann, “Disease guided optimization of the respiratory delivery of microparticulate formulations,” Expert Opinion on Drug Delivery, vol. 5, no. 3, pp. 269–289, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Langer, “New methods of drug delivery,” Science, vol. 249, no. 4976, pp. 1527–1533, 1990. View at Google Scholar · View at Scopus
  13. R. Langer, “Drug delivery and targeting,” Nature, vol. 392, no. 6679, supplement, pp. 5–10, 1998. View at Google Scholar · View at Scopus
  14. D. A. La Van, D. M. Lynn, and R. Langer, “Moving smaller in drug discovery and delivery,” Nature Reviews Drug Discovery, vol. 1, no. 1, pp. 77–84, 2002. View at Google Scholar · View at Scopus
  15. O. C. Farokhzad and R. Langer, “Impact of nanotechnology on drug delivery,” ACS Nano, vol. 3, no. 1, pp. 16–20, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. B. Mishra, B. B. Patel, and S. Tiwari, “Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery,” Nanomedicine, vol. 6, no. 1, pp. e9–e24, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. K. S. Soppimath, T. M. Aminabhavi, A. R. Kulkarni, and W. E. Rudzinski, “Biodegradable polymeric nanoparticles as drug delivery devices,” Journal of Controlled Release, vol. 70, no. 1-2, pp. 1–20, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Panyam and V. Labhasetwar, “Biodegradable nanoparticles for drug and gene delivery to cells and tissue,” Advanced Drug Delivery Reviews, vol. 55, no. 3, pp. 329–347, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. O. M. Koo, I. Rubinstein, and H. Onyuksel, “Role of nanotechnology in targeted drug delivery and imaging: a concise review,” Nanomedicine, vol. 1, no. 3, pp. 193–212, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. P. G. A. Rogueda and D. Traini, “The nanoscale in pulmonary delivery. Part 1: deposition, fate, toxicology and effects,” Expert Opinion on Drug Delivery, vol. 4, no. 6, pp. 595–606, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. P. G. A. Rogueda and D. Traini, “The nanoscale in pulmonary delivery. Part 2: formulation platforms,” Expert Opinion on Drug Delivery, vol. 4, no. 6, pp. 607–620, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Azarmi, W. H. Roa, and R. Löbenberg, “Targeted delivery of nanoparticles for the treatment of lung diseases,” Advanced Drug Delivery Reviews, vol. 60, no. 8, pp. 863–875, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. E. Rytting, J. Nguyen, X. Wang, and T. Kissel, “Biodegradable polymeric nanocarriers for pulmonary drug delivery,” Expert Opinion on Drug Delivery, vol. 5, no. 6, pp. 629–639, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Lebhardt, S. Roesler, M. Beck-Broichsitter, and T. Kissel, “Polymeric nanocarriers for drug delivery to the lung,” Journal of Drug Delivery Science and Technology, vol. 20, no. 3, pp. 171–180, 2010. View at Google Scholar · View at Scopus
  25. C. Vauthier and K. Bouchemal, “Methods for the preparation and manufacture of polymeric nanoparticles,” Pharmaceutical Research, vol. 26, no. 5, pp. 1025–1058, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. C. E. Mora-Huertas, H. Fessi, and A. Elaissari, “Polymer-based nanocapsules for drug delivery,” International Journal of Pharmaceutics, vol. 385, no. 1-2, pp. 113–142, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. J. M. Anderson and M. S. Shive, “Biodegradation and biocompatibility of PLA and PLGA microspheres,” Advanced Drug Delivery Reviews, vol. 28, no. 1, pp. 5–24, 1997. View at Publisher · View at Google Scholar · View at Scopus
  28. I. Bala, S. Hariharan, and M. N. V. R. Kumar, “PLGA nanoparticles in drug delivery: the state of the art,” Critical Reviews in Therapeutic Drug Carrier Systems, vol. 21, no. 5, pp. 387–422, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. C. E. Astete and C. M. Sabliov, “Synthesis and characterization of PLGA nanoparticles,” Journal of Biomaterials Science, Polymer Edition, vol. 17, no. 3, pp. 247–289, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. C. Washington, “Drug release from microdisperse systems: a critical review,” International Journal of Pharmaceutics, vol. 58, no. 1, pp. 1–12, 1990. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Kreuter, Colloidal Drug Delivery Systems, Marcel Dekker, New York, NY, USA, 1994.
  32. M. Sakagami, “In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery,” Advanced Drug Delivery Reviews, vol. 58, no. 9-10, pp. 1030–1060, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Tronde, C. Bosquillon, and B. Forbes, “The isolated perfused lung for drug absorption studies,” in Biotechnology Pharmaceutical Aspects VII, C. Erhardt and K. J. Kim, Eds., vol. 7 of Drug Absorption Studies, pp. 135–163, Springer, Berlin, Germany, 2008. View at Google Scholar
  34. C. A. Fernandes and R. Vanbever, “Preclinical models for pulmonary drug delivery,” Expert opinion on drug delivery, vol. 6, no. 11, pp. 1231–1245, 2009. View at Google Scholar · View at Scopus
  35. J. Kreuter, “Nanoparticles-a historical perspective,” International Journal of Pharmaceutics, vol. 331, no. 1, pp. 1–10, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit, and R. Langer, “Nanocarriers as an emerging platform for cancer therapy,” Nature Nanotechnology, vol. 2, no. 12, pp. 751–760, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. M. J. Hawkins, P. Soon-Shiong, and N. Desai, “Protein nanoparticles as drug carriers in clinical medicine,” Advanced Drug Delivery Reviews, vol. 60, no. 8, pp. 876–885, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Bur, A. Henning, S. Hein, M. Schneider, and C. M. Lehr, “Inhalative nanomedicine-opportunities and challenges,” Inhalation Toxicology, vol. 21, supplement 1, pp. 137–143, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. I. Roy and N. Vij, “Nanodelivery in airway diseases: challenges and therapeutic applications,” Nanomedicine, vol. 6, no. 2, pp. 237–244, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. R. Dhand, “Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol,” Respiratory Care, vol. 47, no. 12, pp. 1406–1416, 2002. View at Google Scholar · View at Scopus
  41. J. C. Waldrep and R. Dhand, “Advanced nebulizer designs employing vibrating mesh/aperture plate technologies for aerosol generation,” Current Drug Delivery, vol. 5, no. 2, pp. 114–119, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. L. A. Dailey, T. Schmehl, T. Gessler et al., “Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features,” Journal of Controlled Release, vol. 86, no. 1, pp. 131–144, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. W. C. Hinds, Aerosol Technology: Properties, Behavior, and Measurements of Airborne Particles, John Wiley & Sons, New York, NY, USA, 1999.
  44. J. D. Crapo, B. E. Barry, P. Gehr, M. Bachofen, and E. R. Weibel, “Cell number and cell characteristics of the normal human lung,” American Review of Respiratory Disease, vol. 126, no. 2, pp. 332–337, 1982. View at Google Scholar
  45. B. Forbes and C. Ehrhardt, “Human respiratory epithelial cell culture for drug delivery applications,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 60, no. 2, pp. 193–205, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. E. R. Weibel, Ed., Morphometry of the Human Lung, Springer, Berlin, Germany, 1963.
  47. C. M. Evans and JA. S. Koo, “Airway mucus: the good, the bad, the sticky,” Pharmacology and Therapeutics, vol. 121, no. 3, pp. 332–348, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. C. Marriott, “Mucus and mucociliary clearance in the respiratory tract,” Advanced Drug Delivery Reviews, vol. 5, no. 1-2, pp. 19–35, 1990. View at Google Scholar · View at Scopus
  49. A. B. Lansley, “Mucociliary clearance and drug delivery via the respiratory tract,” Advanced Drug Delivery Reviews, vol. 11, no. 3, pp. 299–327, 1993. View at Publisher · View at Google Scholar · View at Scopus
  50. L. A. J. M. Creuwels, L. M. G. Van Golde, and H. P. Haagsman, “The pulmonary surfactant system: biochemical and clinical aspects,” Lung, vol. 175, no. 1, pp. 1–39, 1997. View at Google Scholar · View at Scopus
  51. J. Goerke, “Pulmonary surfactant: functions and molecular composition,” Biochimica et Biophysica Acta, vol. 1408, no. 2-3, pp. 79–89, 1998. View at Publisher · View at Google Scholar · View at Scopus
  52. R. Veldhuizen, K. Nag, S. Orgeig, and F. Possmayer, “The role of lipids in pulmonary surfactant,” Biochimica et Biophysica Acta, vol. 1408, no. 2-3, pp. 90–108, 1998. View at Publisher · View at Google Scholar · View at Scopus
  53. J. Pérez-Gil and K. M. W. Keough, “Interfacial properties of surfactant proteins,” Biochimica et Biophysica Acta, vol. 1408, no. 2-3, pp. 203–217, 1998. View at Publisher · View at Google Scholar · View at Scopus
  54. R. Wüstneck, J. Perez-Gil, N. Wüstneck, A. Cruz, V. B. Fainerman, and U. Pison, “Interfacial properties of pulmonary surfactant layers,” Advances in Colloid and Interface Science, vol. 117, no. 1-3, pp. 33–58, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. J. Pérez-Gil, “Structure of pulmonary surfactant membranes and films: the role of proteins and lipid-protein interactions,” Biochimica et Biophysica Acta, vol. 1778, no. 7-8, pp. 1676–1695, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. H. Fehrenbach, “Alveolar epithelial type II cell: defender of the alveolus revisited,” Respiratory Research, vol. 2, no. 1, pp. 33–46, 2001. View at Publisher · View at Google Scholar · View at Scopus
  57. M. Ehrhardt, M. Laue, and K. J. Kim, “In vitro models of the alveolar epithelial barrier,” in Biotechnology Pharmaceutical Aspects VII, C. Erhardt and K. J. Kim, Eds., Drug Absorption Studies, pp. 258–282, Springer, Berlin, Germany, 2008. View at Google Scholar
  58. J. S. Patton, “Mechanisms of macromolecule absorption by the lungs,” Advanced Drug Delivery Reviews, vol. 19, no. 1, pp. 3–36, 1996. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Gumbleton, “Caveolae as potential macromolecule trafficking compartments within alveolar epithelium,” Advanced Drug Delivery Reviews, vol. 49, no. 3, pp. 281–300, 2001. View at Publisher · View at Google Scholar · View at Scopus
  60. J. D. Brain, “Mechanisms, measurement, and significance of lung macrophage function,” Environmental Health Perspectives, vol. 97, pp. 5–10, 1992. View at Google Scholar · View at Scopus
  61. A. Palecanda and L. Kobzik, “Receptors for unopsonized particles: the role of alveolar macrophage scavenger receptors,” Current Molecular Medicine, vol. 1, no. 5, pp. 589–595, 2001. View at Google Scholar · View at Scopus
  62. J. Yu and Y. W. Chien, “Pulmonary drug delivery: physiologic and mechanistic aspects,” Critical Reviews in Therapeutic Drug Carrier Systems, vol. 14, no. 4, pp. 395–453, 1997. View at Google Scholar · View at Scopus
  63. U. Pison, T. Welte, M. Giersig, and D. A. Groneberg, “Nanomedicine for respiratory diseases,” European Journal of Pharmacology, vol. 533, no. 1–3, pp. 341–350, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. J. C. Sung, B. L. Pulliam, and D. A. Edwards, “Nanoparticles for drug delivery to the lungs,” Trends in Biotechnology, vol. 25, no. 12, pp. 563–570, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Smola, T. Vandamme, and A. Sokolowski, “Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases,” International Journal of Nanomedicine, vol. 3, no. 1, pp. 1–19, 2008. View at Google Scholar · View at Scopus
  66. W. Yang, J. I. Peters, and R. O. Williams, “Inhaled nanoparticles. A current review,” International Journal of Pharmaceutics, vol. 356, no. 1-2, pp. 239–247, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. M. M. Bailey and C. J. Berkland, “Nanoparticle formulations in pulmonary drug delivery,” Medicinal Research Reviews, vol. 29, no. 1, pp. 196–212, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. H. M. Mansour, Y. S. Rhee, and X. Wu, “Nanomedicine in pulmonary delivery,” International journal of nanomedicine, vol. 4, pp. 299–319, 2009. View at Google Scholar · View at Scopus
  69. G. Oberdörster, E. Oberdörster, and J. Oberdörster, “Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles,” Environmental Health Perspectives, vol. 113, no. 7, pp. 823–839, 2005. View at Publisher · View at Google Scholar · View at Scopus
  70. M. S. Cartiera, K. M. Johnson, V. Rajendran, M. J. Caplan, and W. M. Saltzman, “The uptake and intracellular fate of PLGA nanoparticles in epithelial cells,” Biomaterials, vol. 30, no. 14, pp. 2790–2798, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. J. S. Patton and R. M. Platz, “Pulmonary delivery of peptides and proteins for systemic action,” Advanced Drug Delivery Reviews, vol. 8, no. 2-3, pp. 179–196, 1992. View at Google Scholar · View at Scopus
  72. P. R. Byron and J. S. Patton, “Drug delivery via the respiratory tract,” Journal of Aerosol Medicine, vol. 7, no. 1, pp. 49–75, 1994. View at Google Scholar · View at Scopus
  73. R. W. Niven, “Delivery of biotherapeutics by inhalation aerosol,” Critical Reviews in Therapeutic Drug Carrier Systems, vol. 12, no. 2-3, pp. 151–231, 1995. View at Google Scholar · View at Scopus
  74. R. U. Agu, M. I. Ugwoke, M. Armand, R. Kinget, and N. Verbeke, “The lung as a route for systemic delivery of therapeutic proteins and peptides,” Respiratory Research, vol. 2, no. 4, pp. 198–209, 2001. View at Publisher · View at Google Scholar · View at Scopus
  75. G. Scheuch, M. J. Kohlhaeufl, P. Brand, and R. Siekmeier, “Clinical perspectives on pulmonary systemic and macromolecular delivery,” Advanced Drug Delivery Reviews, vol. 58, no. 9-10, pp. 996–1008, 2006. View at Publisher · View at Google Scholar · View at Scopus
  76. J. S. Patton and P. R. Byron, “Inhaling medicines: delivering drugs to the body through the lungs,” Nature Reviews Drug Discovery, vol. 6, no. 1, pp. 67–74, 2007. View at Publisher · View at Google Scholar · View at Scopus
  77. R. Siekmeier and G. Scheuch, “Systemic treatment by inhalation of macromolecules—principles, problems, and examples,” Journal of Physiology and Pharmacology, vol. 59, no. 6, pp. 53–79, 2008. View at Google Scholar · View at Scopus
  78. C. Bailey and A. Barnett, “Why is Exubera being withdrawn?” British Medical Journal, vol. 335, no. 7630, p. 1156, 2007. View at Google Scholar
  79. J. Kling, “Inhaled insulin's last gasp?” Nature Biotechnology, vol. 26, no. 5, pp. 479–480, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. T. Volsko and M. D. Reed, “Drugs used in the treatment of asthma: a review of clinical pharmacology and aerosol drug delivery,” Respiratory care clinics of North America, vol. 6, no. 1, pp. 41–55, 2000. View at Google Scholar · View at Scopus
  81. D. D. Sin and S. F. Paul Man, “Inhaled corticosteroids in the long-term management of patients with chronic obstructive pulmonary disease,” Drugs and Aging, vol. 20, no. 12, pp. 867–880, 2003. View at Publisher · View at Google Scholar · View at Scopus
  82. T. Gessler, T. Schmehl, H. Olschewski, F. Grimminger, and W. Seeger, “Aerosolized vasodilators in pulmonary hypertension,” Journal of Aerosol Medicine, vol. 15, no. 2, pp. 117–122, 2002. View at Google Scholar · View at Scopus
  83. H. Olschewski, G. Simonneau, N. Galiè et al., “Inhaled iloprost for severe pulmonary hypertension,” New England Journal of Medicine, vol. 347, no. 5, pp. 322–329, 2002. View at Publisher · View at Google Scholar · View at Scopus
  84. A. R. Clark, “Medical aerosol inhalers: past, present, and future,” Aerosol Science and Technology, vol. 22, no. 4, pp. 374–391, 1995. View at Google Scholar · View at Scopus
  85. I. Gonda, “The ascent of pulmonary drug delivery,” Journal of Pharmaceutical Sciences, vol. 89, no. 7, pp. 940–945, 2000. View at Google Scholar · View at Scopus
  86. P. J. Anderson, “History of aerosol therapy: liquid nebulization to MDIs to DPIs,” Respiratory Care, vol. 50, no. 9, pp. 1139–1150, 2005. View at Google Scholar · View at Scopus
  87. D. E. Geller, “Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler,” Respiratory Care, vol. 50, no. 10, pp. 1313–1321, 2005. View at Google Scholar · View at Scopus
  88. S. P. Newman, “Principles of metered-dose inhaler design,” Respiratory Care, vol. 50, no. 9, pp. 1177–1190, 2005. View at Google Scholar · View at Scopus
  89. P. J. Atkins, “Dry powder inhalers: an overview,” Respiratory Care, vol. 50, no. 10, pp. 1304–1312, 2005. View at Google Scholar · View at Scopus
  90. J. B. Fink, “Metered-dose inhalers, dry powder inhalers, and transitions,” Respiratory Care, vol. 45, no. 6, pp. 623–635, 2000. View at Google Scholar · View at Scopus
  91. P. P. H. Le Brun, A. H. De Boer, H. W. Frijlink, and H. G. M. Heijerman, “A review of the technical aspects of drug nebulization,” Pharmacy World and Science, vol. 22, no. 3, pp. 75–81, 2000. View at Publisher · View at Google Scholar · View at Scopus
  92. O. N. M. McCallion, K. M. G. Taylor, P. A. Bridges, M. Thomas, and A. J. Taylor, “Jet nebulisers for pulmonary drug delivery,” International Journal of Pharmaceutics, vol. 130, no. 1, pp. 1–11, 1996. View at Publisher · View at Google Scholar · View at Scopus
  93. K. M. G. Taylor and O. N. M. McCallion, “Ultrasonic nebulisers for pulmonary drug delivery,” International Journal of Pharmaceutics, vol. 153, no. 1, pp. 93–104, 1997. View at Publisher · View at Google Scholar · View at Scopus
  94. M. Knoch and M. Keller, “The customised electronic nebuliser: a new category of liquid aerosol drug delivery systems,” Expert Opinion on Drug Delivery, vol. 2, no. 2, pp. 377–390, 2005. View at Publisher · View at Google Scholar · View at Scopus
  95. S. Gill, R. Löbenberg, T. Ku, S. Azarmi, W. Roa, and E. J. Prenner, “Nanoparticles: characteristics, mechanisms of action, and toxicity in pulmonary drug delivery—a review,” Journal of Biomedical Nanotechnology, vol. 3, no. 2, pp. 107–119, 2007. View at Publisher · View at Google Scholar · View at Scopus
  96. J. W. Card, D. C. Zeldin, J. C. Bonner, and E. R. Nestmann, “Pulmonary applications and toxicity of engineered nanoparticles,” American Journal of Physiology, vol. 295, no. 3, pp. L400–L411, 2008. View at Publisher · View at Google Scholar · View at Scopus
  97. W. H. De Jong and P. J. A. Borm, “Drug delivery and nanoparticles: applications and hazards,” International Journal of Nanomedicine, vol. 3, no. 2, pp. 133–149, 2008. View at Google Scholar · View at Scopus
  98. K. R. Vega-Villa, J. K. Takemoto, J. A. Yáñez, C. M. Remsberg, M. L. Forrest, and N. M. Davies, “Clinical toxicities of nanocarrier systems,” Advanced Drug Delivery Reviews, vol. 60, no. 8, pp. 929–938, 2008. View at Publisher · View at Google Scholar · View at Scopus
  99. M. Caldorera-Moore and N. A. Peppas, “Micro- and nanotechnologies for intelligent and responsive biomaterial-based medical systems,” Advanced Drug Delivery Reviews, vol. 61, no. 15, pp. 1391–1401, 2009. View at Publisher · View at Google Scholar · View at Scopus
  100. L. A. Dailey and T. Kissel, “New poly(lactic-co-glycolic acid) derivatives: modular polymers with tailored properties,” Drug Discovery Today: Technologies, vol. 2, no. 1, pp. 7–13, 2005. View at Publisher · View at Google Scholar · View at Scopus
  101. L. A. Dailey, M. Wittmar, and T. Kissel, “The role of branched polyesters and their modifications in the development of modern drug delivery vehicles,” Journal of Controlled Release, vol. 101, no. 1–3, pp. 137–149, 2005. View at Publisher · View at Google Scholar
  102. F. Unger, M. Wittmar, F. Morell, and T. Kissel, “Branched polyesters based on poly[vinyl-3-(dialkylamino)alkylcarbamate-co-vinyl acetate-co-vinyl alcohol]-graft-poly(d,l-lactide-co-glycolide): effects of polymer structure on in vitro degradation behaviour,” Biomaterials, vol. 29, no. 13, pp. 2007–2014, 2008. View at Publisher · View at Google Scholar · View at Scopus
  103. F. Unger, M. Wittmar, and T. Kissel, “Branched polyesters based on poly[vinyl-3-(dialkylamino)alkylcarbamate-co-vinyl acetate-co-vinyl alcohol]-graft-poly(d,l-lactide-co-glycolide): effects of polymer structure on cytotoxicity,” Biomaterials, vol. 28, no. 9, pp. 1610–1619, 2007. View at Publisher · View at Google Scholar · View at Scopus
  104. L. A. Dailey, N. Jekel, L. Fink et al., “Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung,” Toxicology and Applied Pharmacology, vol. 215, no. 1, pp. 100–108, 2006. View at Publisher · View at Google Scholar · View at Scopus
  105. L. A. Dailey, E. Kleemann, M. Wittmar et al., “Surfactant-free, biodegradable nanoparticles for aerosol therapy based on the branched polyesters, DEAPA-PVAL-g-PLGA,” Pharmaceutical Research, vol. 20, no. 12, pp. 2011–2020, 2003. View at Publisher · View at Google Scholar · View at Scopus
  106. M. Beck-Broichsitter, J. Gauss, C. B. Packhaeuser et al., “Pulmonary drug delivery with aerosolizable nanoparticles in an ex vivo lung model,” International Journal of Pharmaceutics, vol. 367, no. 1-2, pp. 169–178, 2009. View at Publisher · View at Google Scholar · View at Scopus
  107. J. Fu, J. Fiegel, E. Krauland, and J. Hanes, “New polymeric carriers for controlled drug delivery following inhalation or injection,” Biomaterials, vol. 23, no. 22, pp. 4425–4433, 2002. View at Publisher · View at Google Scholar · View at Scopus
  108. J. Fu, J. Fiegel, and J. Hanes, “Synthesis and characterization of PEG-based ether-anhydride terpolymers: novel polymers for controlled drug delivery,” Macromolecules, vol. 37, no. 19, pp. 7174–7180, 2004. View at Publisher · View at Google Scholar · View at Scopus
  109. J. Fiegel, J. Fu, and J. Hanes, “Poly(ether-anhydride) dry powder aerosols for sustained drug delivery in the lungs,” Journal of Controlled Release, vol. 96, no. 3, pp. 411–423, 2004. View at Publisher · View at Google Scholar · View at Scopus
  110. J. M. Barichello, M. Morishita, K. Takayama, and T. Nagai, “Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method,” Drug Development and Industrial Pharmacy, vol. 25, no. 4, pp. 471–476, 1999. View at Publisher · View at Google Scholar · View at Scopus
  111. T. Govender, S. Stolnik, M. C. Garnett, L. Illum, and S. S. Davis, “PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug,” Journal of Controlled Release, vol. 57, no. 2, pp. 171–185, 1999. View at Publisher · View at Google Scholar · View at Scopus
  112. M. Wittmar, F. Unger, and T. Kissel, “Biodegradable brushlike branched polyesters containing a charge-modified poly (vinyl alcohol) backbone as a platform for drug delivery systems: synthesis and characterization,” Macromolecules, vol. 39, no. 4, pp. 1417–1424, 2006. View at Publisher · View at Google Scholar · View at Scopus
  113. X. Wang, X. Xie, C. Cai, E. Rytting, T. Steele, and T. Kissel, “Biodegradable branched polyesters poly(vinyl sulfonate-covinyl alcohol)-graft poly(D,L-lactic-coglycolic acid) as a negatively charged polyelectrolyte platform for drug delivery: synthesis and characterization,” Macromolecules, vol. 41, no. 8, pp. 2791–2799, 2008. View at Publisher · View at Google Scholar · View at Scopus
  114. J. Heyder, J. Gebhart, G. Rudolf, C. F. Schiller, and W. Stahlhofen, “Deposition of particles in the human respiratory tract in the size range 0.005–15 μm,” Journal of Aerosol Science, vol. 17, no. 5, pp. 811–825, 1986. View at Google Scholar · View at Scopus
  115. C. Jaafar-Maalej, V. Andrieu, A. Elaissari, and H. Fessi, “Assessment methods of inhaled aerosols: technical aspects and applications,” Expert Opinion on Drug Delivery, vol. 6, no. 9, pp. 941–959, 2009. View at Publisher · View at Google Scholar · View at Scopus
  116. J. Liu, T. Gong, H. Fu et al., “Solid lipid nanoparticles for pulmonary delivery of insulin,” International Journal of Pharmaceutics, vol. 356, no. 1-2, pp. 333–344, 2008. View at Publisher · View at Google Scholar · View at Scopus
  117. J. Hureaux, F. Lagarce, F. Gagnadoux et al., “Lipid nanocapsules: ready-to-use nanovectors for the aerosol delivery of paclitaxel,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 73, no. 2, pp. 239–246, 2009. View at Publisher · View at Google Scholar · View at Scopus
  118. T. Ghazanfari, A. M. A. Elhissi, Z. Ding, and K. M. G. Taylor, “The influence of fluid physicochemical properties on vibrating-mesh nebulization,” International Journal of Pharmaceutics, vol. 339, no. 1-2, pp. 103–111, 2007. View at Publisher · View at Google Scholar · View at Scopus
  119. A. H. L. Chow, H. H. Y. Tong, P. Chattopadhyay, and B. Y. Shekunov, “Particle engineering for pulmonary drug delivery,” Pharmaceutical Research, vol. 24, no. 3, pp. 411–437, 2007. View at Publisher · View at Google Scholar · View at Scopus
  120. P. C. Seville, H. Y. Li, and T. P. Learoyd, “Spray-dried powders for pulmonary drug delivery,” Critical Reviews in Therapeutic Drug Carrier Systems, vol. 24, no. 4, pp. 307–360, 2007. View at Google Scholar · View at Scopus
  121. D. Lemoine, C. Francois, F. Kedzierewicz, V. Preat, M. Hoffman, and P. Maincent, “Stability study of nanoparticles of poly(ε-caprolactone), poly(D,L-lactide) and poly(D,L-lactide-co-glycolide),” Biomaterials, vol. 17, no. 22, pp. 2191–2197, 1996. View at Publisher · View at Google Scholar · View at Scopus
  122. M. S. Muthu and SI. S. Feng, “Pharmaceutical stability aspects of nanomedicines,” Nanomedicine, vol. 4, no. 8, pp. 857–860, 2009. View at Publisher · View at Google Scholar · View at Scopus
  123. W. Abdelwahed, G. Degobert, S. Stainmesse, and H. Fessi, “Freeze-drying of nanoparticles: formulation, process and storage considerations,” Advanced Drug Delivery Reviews, vol. 58, no. 15, pp. 1688–1713, 2006. View at Publisher · View at Google Scholar · View at Scopus
  124. P. Tewa-Tagne, S. Briançon, and H. Fessi, “Preparation of redispersible dry nanocapsules by means of spray-drying: development and characterisation,” European Journal of Pharmaceutical Sciences, vol. 30, no. 2, pp. 124–135, 2007. View at Publisher · View at Google Scholar · View at Scopus
  125. G. Pilcer and K. Amighi, “Formulation strategy and use of excipients in pulmonary drug delivery,” International Journal of Pharmaceutics, vol. 392, no. 1-2, pp. 1–19, 2010. View at Publisher · View at Google Scholar · View at Scopus
  126. K. Tomoda, T. Ohkoshi, K. Hirota et al., “Preparation and properties of inhalable nanocomposite particles for treatment of lung cancer,” Colloids and Surfaces B, vol. 71, no. 2, pp. 177–182, 2009. View at Publisher · View at Google Scholar · View at Scopus
  127. J. C. Sung, D. J. Padilla, L. Garcia-Contreras et al., “Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery,” Pharmaceutical Research, vol. 26, no. 8, pp. 1847–1855, 2009. View at Publisher · View at Google Scholar · View at Scopus
  128. L. Ely, W. Roa, W. H. Finlay, and R. Löbenberg, “Effervescent dry powder for respiratory drug delivery,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 65, no. 3, pp. 346–353, 2007. View at Publisher · View at Google Scholar · View at Scopus
  129. L. Shi, C. J. Plumley, and C. Berkland, “Biodegradable nanoparticle flocculates for dry powder aerosol formulation,” Langmuir, vol. 23, no. 22, pp. 10897–10901, 2007. View at Publisher · View at Google Scholar · View at Scopus
  130. L. J. Peek, L. Roberts, and C. Berkland, “Poly(D,L-lactide-co-glycolide) nanoparticle agglomerates as carriers in dry powder aerosol formulation of proteins,” Langmuir, vol. 24, no. 17, pp. 9775–9783, 2008. View at Publisher · View at Google Scholar · View at Scopus
  131. N. R. Mathias, F. Yamashita, and V. H. L. Lee, “Respiratory epithelial cell culture models for evaluation of ion and drug transport,” Advanced Drug Delivery Reviews, vol. 22, no. 1-2, pp. 215–249, 1996. View at Publisher · View at Google Scholar · View at Scopus
  132. A. Steimer, E. Haltner, and C. M. Lehr, “Cell culture models of the respiratory tract relevant to pulmonary drug delivery,” Journal of Aerosol Medicine, vol. 18, no. 2, pp. 137–182, 2005. View at Publisher · View at Google Scholar · View at Scopus
  133. J. L. Sporty, L. Horálková, and C. Ehrhardt, “In vitro cell culture models for the assessment of pulmonary drug disposition,” Expert Opinion on Drug Metabolism and Toxicology, vol. 4, no. 4, pp. 333–345, 2008. View at Publisher · View at Google Scholar · View at Scopus
  134. G. L. Amidon, H. Lennernas, V. P. Shah, and J. R. Crison, “A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability,” Pharmaceutical Research, vol. 12, no. 3, pp. 413–420, 1995. View at Google Scholar · View at Scopus
  135. H. Eixarch, E. Haltner-Ukomadu, C. Beisswenger, and U. Bock, “Drug delivery to the lung: permeability and physicochemical characteristics of drugs as the basis for a pulmonary biopharmaceutical classification system (pBCS),” Journal of Epithelial Biology and Pharmacology, vol. 3, pp. 1–14, 2010. View at Publisher · View at Google Scholar · View at Scopus
  136. S. A. Cryan, N. Sivadas, and L. Garcia-Contreras, “In vivo animal models for drug delivery across the lung mucosal barrier,” Advanced Drug Delivery Reviews, vol. 59, no. 11, pp. 1133–1151, 2007. View at Publisher · View at Google Scholar · View at Scopus
  137. P. Gerde, “Animal models and their limitations: on the problem of high-to-low dose extrapolations following inhalation exposures,” Experimental and Toxicologic Pathology, vol. 57, no. 1, supplement, pp. 143–146, 2005. View at Publisher · View at Google Scholar
  138. R. W. Niemeier, “Isolated perfused rabbit lung: a critical appraisal,” Environmental Health Perspectives, vol. 16, pp. 67–71, 1976. View at Google Scholar · View at Scopus
  139. H. M. Mehendale, L. S. Angevine, and Y. Ohmiya, “The isolated perfused lung. A critical evaluation,” Toxicology, vol. 21, no. 1, pp. 1–36, 1981. View at Publisher · View at Google Scholar · View at Scopus
  140. R. W. Niemeier, “The isolated perfused lung,” Environmental Health Perspectives, vol. 56, pp. 35–41, 1984. View at Google Scholar · View at Scopus
  141. W. Seeger, D. Walmrath, F. Grimminger et al., “Adult respiratory distress syndrome: model systems using isolated perfused rabbit lungs,” Methods in Enzymology, vol. 233, pp. 549–584, 1994. View at Publisher · View at Google Scholar · View at Scopus
  142. P. R. Byron and R. W. Niven, “A novel dosing method for drug administration to the airways of the isolated perfused rat lung,” Journal of Pharmaceutical Sciences, vol. 77, no. 8, pp. 693–695, 1988. View at Google Scholar · View at Scopus
  143. P. R. Byron, N. S. R. Roberts, and A. R. Clark, “An isolated perfused rat lung preparation for the study of aerosolized drug deposition and absorption,” Journal of Pharmaceutical Sciences, vol. 75, no. 2, pp. 168–171, 1986. View at Google Scholar · View at Scopus
  144. R. W. Niven and P. R. Byron, “Solute absorption from the airways of the isolated rat lung. I. The use of absorption data to quantify drug dissolution or release in the respiratory tract,” Pharmaceutical Research, vol. 5, no. 9, pp. 574–579, 1988. View at Google Scholar · View at Scopus
  145. R. W. Niven and P. R. Byron, “Solute absorption from the airways of the isolated rat lung II. Eeffect of surfaccants on absorption of fluorescein,” Pharmaceutical Research, vol. 7, no. 1, pp. 8–13, 1990. View at Google Scholar
  146. R. W. Niven, F. Rypacek, and P. R. Byron, “Solute absorption from the airways of the isolated rat lung. III. Absorption of several peptidase-resistant, synthetic polypeptides: poly-(2-hydroxyethyl)-aspartamides,” Pharmaceutical Research, vol. 7, no. 10, pp. 990–994, 1990. View at Google Scholar · View at Scopus
  147. P. R. Byron, Z. Sun, H. Katayama, and F. Rypacek, “Solute absorption from the airways of the isolated rat lung. IV. mechanisms of absorption of fluorophore-labeled poly-α,β-[N(2-hydroxyethyl)-DL-aspartamide],” Pharmaceutical Research, vol. 11, no. 2, pp. 221–225, 1994. View at Publisher · View at Google Scholar · View at Scopus
  148. J. Z. Sun, P. R. Byron, and F. Rypacek, “Solute absorption from the airways of the isolated rat lung. V. Charge effects on the absorption of copolymers of N(2-hydroxyethyl)-DL-aspartamide with DL-aspartic acid or dimethylaminopropyl-DL-aspartamide,” Pharmaceutical Research, vol. 16, no. 7, pp. 1104–1108, 1999. View at Publisher · View at Google Scholar · View at Scopus
  149. M. Sakagami, P. R. Byron, J. Venitz, and F. Rypacek, “Solute disposition in the rat lung in vivo and in vitro: determining regional absorption kinetics in the presence of mucociliary escalator,” Journal of Pharmaceutical Sciences, vol. 91, no. 2, pp. 594–604, 2002. View at Publisher · View at Google Scholar · View at Scopus
  150. M. Sakagami, P. R. Byron, and F. Rypacek, “Biochemical evidence for transcytotic absorption of polyaspartamide from the rat lung: effects of temperature and metabolic inhibitors,” Journal of Pharmaceutical Sciences, vol. 91, no. 9, pp. 1958–1968, 2002. View at Publisher · View at Google Scholar · View at Scopus
  151. Y. Pang, M. Sakagami, and P. R. Byron, “The pharmacokinetics of pulmonary insulin in the in vitro isolated perfused rat lung: implications of metabolism and regional deposition,” European Journal of Pharmaceutical Sciences, vol. 25, no. 4-5, pp. 369–378, 2005. View at Publisher · View at Google Scholar · View at Scopus
  152. Y. Pang, M. Sakagami, and P. R. Byron, “Insulin self-association: effects on lung disposition kinetics in the airways of the isolated perfused rat lung (IPRL),” Pharmaceutical Research, vol. 24, no. 9, pp. 1636–1644, 2007. View at Publisher · View at Google Scholar · View at Scopus
  153. A. Ryrfeldt, G. Persson, and E. Nilsson, “Pulmonary disposition of the potent glucocorticoid budesonide, evaluated in an isolated perfused rat lung model,” Biochemical Pharmacology, vol. 38, no. 1, pp. 17–22, 1989. View at Publisher · View at Google Scholar · View at Scopus
  154. M. J. Jesús Valle, F. González López, and A. Sánchez Navarro, “Pulmonary versus systemic delivery of levofloxacin. The isolated lung of the rat as experimental approach for assessing pulmonary inhalation,” Pulmonary Pharmacology and Therapeutics, vol. 21, no. 2, pp. 298–303, 2008. View at Publisher · View at Google Scholar · View at Scopus
  155. P. Ewing, S. J. Eirefelt, P. Andersson, A. Blomgren, A. Ryrfeldt, and P. Gerde, “Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline,” Journal of Aerosol Medicine, vol. 21, no. 2, pp. 169–180, 2008. View at Publisher · View at Google Scholar · View at Scopus
  156. A. Tronde, BO. Nordén, A. B. Jeppsson et al., “Drug absorption from the isolated perfused rat lung—correlations with drug physicochemical properties and epithelial permeability,” Journal of Drug Targeting, vol. 11, no. 1, pp. 61–74, 2003. View at Publisher · View at Google Scholar · View at Scopus
  157. A. Tronde, E. Krondahl, H. Von Euler-Chelpin et al., “High airway-to-blood transport of an opioid tetrapeptide in the isolated rat lung after aerosol delivery,” Peptides, vol. 23, no. 3, pp. 469–478, 2002. View at Publisher · View at Google Scholar
  158. F. Kroll, J. A. Karlsson, E. Nilsson, A. Ryrfeldt, and C. G. A. Persson, “Rapid clearance of xanthines from airway and pulmonary tissues,” American Review of Respiratory Disease, vol. 141, no. 5, pp. 1167–1171, 1990. View at Google Scholar · View at Scopus
  159. K. Lahnstein, T. Schmehl, U. Rüsch, M. Rieger, W. Seeger, and T. Gessler, “Pulmonary absorption of aerosolized fluorescent markers in the isolated rabbit lung,” International Journal of Pharmaceutics, vol. 351, no. 1-2, pp. 158–164, 2008. View at Publisher · View at Google Scholar · View at Scopus
  160. R. T. Schermuly, A. Schulz, H. A. Ghofrani et al., “Comparison of pharmacokinetics and vasodilatory effect of nebulized and infused iloprost in experimental pulmonary hypertension: rapid tolerance development,” Journal of Aerosol Medicine, vol. 19, no. 3, pp. 353–363, 2006. View at Publisher · View at Google Scholar
  161. M. Beck-Broichsitter, J. Gauss, T. Gessler, W. Seeger, T. Kissel, and T. Schmehl, “Pulmonary targeting with biodegradable salbutamol-loaded nanoparticles,” Journal of Aerosol Medicine, vol. 23, no. 1, pp. 47–57, 2010. View at Publisher · View at Google Scholar · View at Scopus
  162. R. K. Brazzell, R. B. Smith, and H. B. Kostenbauder, “Isolated perfused rabbit lung as a model for intravascular and intrabronchial administration of bronchodilator drugs I: isoproterenol,” Journal of Pharmaceutical Sciences, vol. 71, no. 11, pp. 1268–1274, 1982. View at Google Scholar · View at Scopus
  163. R. K. Brazzell and H. B. Kostenbauder, “Isolated perfused rabbit lung as a model for intravascular and intrabronchial administration of bronchodilator drugs II: isoproterenol prodrugs,” Journal of Pharmaceutical Sciences, vol. 71, no. 11, pp. 1274–1281, 1982. View at Google Scholar · View at Scopus
  164. O. G. Raabe, H. S. Yeh, G. J. Newton, R. F. Phalen, and D. J. Velasquez, “Deposition of inhaled monodispers aerosols in small rodents,” in Inhaled Particles IV, W. H. Walton, Ed., pp. 3–21, Pergamon Press, Oxford, UK, 1977. View at Google Scholar
  165. A. Tronde, G. Baran, S. Eirefelt, H. Lennernäs, and U. H. Bengtsson, “Miniaturized nebulization catheters: a new approach for delivery of defined aerosol doses to the rat lung,” Journal of Aerosol Medicine, vol. 15, no. 3, pp. 283–296, 2002. View at Google Scholar · View at Scopus
  166. C. Hofstetter, M. Flonder, E. Thein et al., “Aerosol delivery during mechanical ventilation to the rat,” Experimental Lung Research, vol. 30, no. 7, pp. 635–651, 2004. View at Publisher · View at Google Scholar
  167. R. J. MacLoughlin, B. D. Higgins, J. G. Laffey, and T. O'Brien, “Optimized aerosol delivery to a mechanically ventilated rodent,” Journal of Aerosol Medicine, vol. 22, no. 4, pp. 323–332, 2009. View at Publisher · View at Google Scholar · View at Scopus
  168. R. W. Niemeier and E. Bingham, “An isolated perfused lung preparation for metabolic studies,” Life Sciences, vol. 11, no. 16, pp. 807–820, 1972. View at Google Scholar · View at Scopus
  169. F. Kroll, J.-A. Karlsson, and E. Nilsson, “Lung mechanics of the guinea-pig isolated perfused lung,” Acta Physiologica Scandinavica, vol. 128, no. 1, pp. 1–8, 1986. View at Google Scholar
  170. S. Uhlig and O. Heiny, “Measuring the weight of the isolated perfused rat lung during negative pressure ventilation,” Journal of Pharmacological and Toxicological Methods, vol. 33, no. 3, pp. 147–152, 1995. View at Publisher · View at Google Scholar · View at Scopus
  171. S. Uhlig and L. Wollin, “An improved setup for the isolated perfused rat lung,” Journal of Pharmacological and Toxicological Methods, vol. 31, no. 2, pp. 85–94, 1994. View at Publisher · View at Google Scholar · View at Scopus
  172. X. Liu, J. Y. Wang, A. M. Khlentzos et al., “Influence of perfusate composition on drug disposition in the in-situ perfused rat lung,” International Journal of Pharmaceutics, vol. 382, no. 1-2, pp. 192–197, 2009. View at Publisher · View at Google Scholar · View at Scopus
  173. J. Hamoir, A. Nemmar, D. Halloy et al., “Effect of polystyrene particles on lung microvascular permeability in isolated perfused rabbit lungs: role of size and surface properties,” Toxicology and Applied Pharmacology, vol. 190, no. 3, pp. 278–285, 2003. View at Publisher · View at Google Scholar · View at Scopus
  174. A. Nemmar, J. Hamoir, B. Nemery, and P. Gustin, “Evaluation of particle translocation across the alveolo-capillary barrier in isolated perfused rabbit lung model,” Toxicology, vol. 208, no. 1, pp. 105–113, 2005. View at Publisher · View at Google Scholar · View at Scopus
  175. A. Tronde, BO. Nordén, H. Marchner, A. K. Wendel, H. Lennernäs, and U. H. Bengtsson, “Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs,” Journal of Pharmaceutical Sciences, vol. 92, no. 6, pp. 1216–1233, 2003. View at Publisher · View at Google Scholar · View at Scopus
  176. F. Manford, A. Tronde, A. B. Jeppsson, N. Patel, F. Johansson, and B. Forbes, “Drug permeability in 16HBE14o- airway cell layers correlates with absorption from the isolated perfused rat lung,” European Journal of Pharmaceutical Sciences, vol. 26, no. 5, pp. 414–420, 2005. View at Publisher · View at Google Scholar · View at Scopus
  177. E. Rytting, M. Bur, R. Cartier et al., “In vitro and in vivo performance of biocompatible negatively-charged salbutamol-loaded nanoparticles,” Journal of Controlled Release, vol. 141, no. 1, pp. 101–107, 2010. View at Publisher · View at Google Scholar · View at Scopus